Used primarily to prevent vasospasm following subarachnoid hemorrhage, this compound helps improve neurological outcomes by maintaining cerebral blood flow. It selectively acts on cerebral arteries, reducing the risk of ischemic damage after aneurysmal bleeding. Due to its ability to cross the blood-brain barrier, it is especially effective in targeting vascular smooth muscle in the brain. Administered orally or via enteral feeding tubes in clinical settings, it is typically started within 96 hours of hemorrhage and continued for 21 days. Its neuroprotective properties make it a key treatment in acute stroke management related to aneurysms.